CTI BioPharma Announces Oral Presentation at the 62nd American Society of Hematology Meeting

Rhea-AI Summary

CTI BioPharma Corp. (Nasdaq: CTIC) announced an oral presentation highlighting the development of pacritinib for graft versus host disease (GVHD) at the 62^nd American Society of Hematology Annual Meeting, scheduled for December 5-8, 2020. The abstract titled Biological and Clinical Impact of JAK2/mTOR Blockade in GVHD Prevention will be presented by Dr. Joseph Pidala during a session on December 6, 2020, at 10:00 a.m. PT. This presentation underscores CTIC's focus on innovative therapies targeting unmet medical needs in blood-related cancers.

Positive

• Pacritinib development program for GVHD highlighted at a major conference.
• Presentation by Dr. Joseph Pidala indicates strong academic support.

Negative

• None.

SEATTLE, Nov. 4, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation supporting the Company's pacritinib development program in graft versus host disease (GVHD) at the 62^nd American Society of Hematology (ASH) Annual Meeting & Exposition, being held virtually December 5- 8, 2020.

The details of the presentation are as follows:

Abstract Title: Biological and Clinical Impact of JAK2/mTOR Blockade in GVHD Prevention: Preclinical and Phase I Trial Results
Session Name: Clinical Allogeneic Transplantation; Acute and Chronic GVHD, Immune Reconstitution Phase I and II Trials
Session Number: 722
Session Date: Sunday, December 6, 2020
Session Time: 9:30 a.m. - 11:00 a.m. PT
Presentation Time: 10:00 a.m. PT
Presenter: Dr. Joseph Pidala

A copy of the abstract is available here.

About CTI BioPharma Corp.

We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

CTI BioPharma Investor Contacts:

Maeve Conneighton/Maghan Meyers
+212-600-1902
cti@argotpartners.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-oral-presentation-at-the-62nd-american-society-of-hematology-meeting-301166463.html

SOURCE CTI BioPharma Corp.

FAQ

What is CTI BioPharma's announcement about pacritinib?

CTI BioPharma announced an oral presentation at the 62nd American Society of Hematology Annual Meeting regarding pacritinib's development for graft versus host disease.

When is the presentation on pacritinib scheduled?

The presentation on pacritinib is scheduled for December 6, 2020, at 10:00 a.m. PT.

Who is presenting the pacritinib study at the ASH meeting?

Dr. Joseph Pidala will present the pacritinib study at the ASH meeting.

What is the focus of CTI BioPharma's research?

CTI BioPharma focuses on developing targeted therapies for blood-related cancers, particularly myelofibrosis.